Shiyao Liu Priti Patel Federico Rotolo Emmanuel Mitry Ira Pastan 0 Francis Giles on behalf of the Study investigators 0 Clinical Immunotherapy Section, Laboratory of Molecular Biology, National Cancer
BackgroundDocetaxel–cisplatin-5-FU chemotherapy is superior to 5-FU-cisplatin in terms of response rate and survival in advanced gastric cancer (AGC), but is more toxic. Oxaliplatin is better tolerated than cisplatin, which it can effectively replace in this setting. We hypothesize that incorporating docetaxel into a simplified FOLFOX regimen should be a tolerable and effective...
Background:Small bowel adenocarcinoma (SBA) is a rare tumour with a poor prognosis. Molecular biology data on SBA carcinogenesis are lacking.Methods:Expression of HER2, β-catenin, p53 and mismatch repair (MMR) protein was assessed by immunohistochemistry. KRAS, V600E BRAF mutations and microsatellite instability were investigated.Results:We obtained samples from 63 SBA patients...
Background The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal cancer (mCRC). However, it was reported to have no efficacy in 3rd or later-line, alone or with 5FU. The aim of this study was to evaluate the activity of...
) Author information AffiliationsGastroenterology and Digestive Oncology Unit, Assistance Publique Hôpitaux de Paris, Hôpital Ambroise Paré, Boulogne Billancourt, FranceAstrid Lièvre, Emmanuel Mitry, Céline ... , Emmanuel Mitry & Philippe RougierDigestive Oncology Unit, Centre Régional de Lutte contre le Cancer Val d'Aurelle - Paul Lamarque, Montpellier, FranceEmmanuelle Samalin, Eric Assenat, Christine Boyer-Gestin